RSS

Kyowa Hakko Kirin

The European Commission (EC) has revealed its decision to grant conditional marketing authorisation to Kyowa Kirin for Crysvita (burosumab) to treat X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children & adolescents Read more

Recipharm was informed on 20 September 2013 by the R&D-based pharmaceutical company Kyowa Hakko Kirin Co. Ltd. that the Abstral sublingual (under the tongue) tablet has been approved for manufacturing and marketing by Japan's Ministry of Health... Read more

Technology